LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study

Abstract

BackgroundIn ph 2 studies, baricitinib (bari) improved disease activity with an acceptable safety profile in patients (pts) with active RA and inadequate response (IR) to conventional DMARDs (cDMARDs).ObjectivesTo report results...